Levidcen (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which plays a key role in regulating neurotransmitter release. This binding modulates synaptic transmission, lowering neuronal excitability and stabilizing firing patterns, thereby decreasing the likelihood of seizure initiation and spread.

The dosage of Levidcen is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. The prescriber determines the appropriate starting dose and any necessary titration schedule to achieve optimal seizure control.

Safety data for levetiracetam in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To request Levidcen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any required import documentation.

Levidcen (levetiracetam) offers a favorable safety profile and minimal drug‑enzyme interactions compared with many older antiepileptics such as carbamazepine or valproate. It does not require routine therapeutic drug monitoring and is often preferred when patients need a medication with fewer hepatic metabolism concerns.

Levidcen should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Levidcen is taken orally, usually as a tablet, with or without food. The exact timing and whether it is taken once or twice daily depends on the prescriber’s instructions and the patient’s individual treatment plan.

Serious risks include severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, significant mood changes including depression or suicidal thoughts, and hematologic abnormalities like thrombocytopenia. Patients should seek immediate medical attention if they experience rash, mood swings, or unexplained bruising.

Levidcen is contraindicated in patients with known hypersensitivity to levetiracetam or any of its excipients. Caution is also advised for individuals with severe renal impairment who have not had dose adjustments, and for those with a history of serious psychiatric disorders unless closely monitored.